Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Philip Hujdic

Physician Assistant, Surgical Renton, WA Physician Assistant

NPI 1346511631 CMS profile 11166870

4011 Talbot Rd S Ste 300, Renton, WA 98055

Open in the dashboard

General payments

$17,094

43 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Philip Hujdic of Renton, WA is reported in the CMS Open Payments database as having received $17,094 across 43 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Surgical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,326 11
2024 General $5,681 11
2023 General $709 4
2022 General $242 2
2021 General $136 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philip Hujdic
  • Physician Assistant, Surgical median
  • Middle half of Physician Assistant, Surgical
  • National median

In program year 2025, general payments to Philip Hujdic were reported at $10,326. Among 8,152 Physician Assistant, Surgical profiles paid that year, the median was $146 and the middle half received between $51 and $385.

Show as a table
Year Philip Hujdic Physician Assistant, Surgical median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $136 $111 $36–$285 $132
2022 $242 $126 $44–$350 $149
2023 $709 $137 $47–$355 $160
2024 $5,681 $146 $49–$384 $164
2025 $10,326 $146 $51–$385 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Solventum Corporation $15,714 18 payments
  2. DePuy Synthes Sales Inc. $796 3 payments
  3. Conformis, Inc. $168 1 payment
  4. Heron Therapeutics, Inc. $146 2 payments
  5. Horizon Therapeutics plc $121 14 payments
  6. KCI USA, Inc $74 1 payment
  7. Medical Device Business Services, Inc. $34 2 payments
  8. Smith+Nephew, Inc. $25 1 payment
  9. Flexion Therapeutics, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,820 3 payments
  2. Travel and Lodging $7,157 13 payments
  3. Food and Beverage $1,117 27 payments
Products named General payments · program years 2021–2025
  1. PREVENA $12,822 16 payments
  2. PREVENA RESTOR ARTHROFORM $5,584 9 payments
  3. 3M DuraPrep Surgical $5,133 2 payments
  4. PREVENA RESTOR BELLAFORM $4,895 4 payments
  5. 3M Ioban $2,892 2 payments
  6. Ioban 2 $2,856 4 payments
  7. ATTUNE $709 4 payments
  8. PREVENA RESTOR AXIOFORM $615 4 payments
  9. V.A.C.ULTA $470 3 payments
  10. iTotal Identity PS $168 1 payment
  11. Other $308 18 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

968

Median for Physician Assistant: 241

Drug cost

$9,712

Median for Physician Assistant: $4,110

Branded share of claims

2.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 12 $3,218
Oxycodone Hcl Generic 261 $1,960
Ondansetron Hcl Generic 266 $1,342
Diclofenac Sodium Generic 102 $967
Cephalexin Generic 41 $774
Cefadroxil Generic 105 $582
Methylprednisolone Generic 47 $403
Meloxicam Generic 72 $192
Hydromorphone Hcl Generic 16 $128
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 13 $92

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$64,136

Of which drugs: $9,347

Medicare patients

313

Average age 75

Services billed

2,198

211 women, 102 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 74%
Depression 24%
Diabetes 22%
Osteoporosis 19%
Chronic kidney disease 18%
Atrial fibrillation 17%
Ischemic heart disease 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 23 1,232 $8,514
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 216 $167

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

43 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record